EUVIMEDEUVIMED entdecken
Crossref

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668e ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Heart Failure, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesHeart FailureDiabetes Mellitus, Type 2Renal Insufficiency, ChronicHumansNaphthyridines

Stichwörter der Autor:innen

ACE inhibitorsARBsAldactoneInspraKerendiaadverse effectschronic kidney diseasedosageefficacyeplerenonefinerenonemetforminsafetyspironolactonetype 2 diabetes

Substanzen

finerenoneNaphthyridines

Zitieren

APA

(2023). In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668e

Vancouver

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668e

BibTeX
@article{euvimed2023,
  title = {In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668e}
}
Kostenlos starten →